Named on 14 rounds in the feed, most often at Series A and in Biotech.
Rounds from 2021-01-07 to 2026-11-10
ROUNDS
14
led 2, joined 12
LED ROUNDS · USD
$36.3M
across 2 rounds · 2 co-led, split evenly
CO-INVESTORS
69
most often with Sanofi Ventures
Named on 14 rounds in the feed, most often at Series A and in Biotech.
Rounds from 2021-01-07 to 2026-11-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
PsiThera A biotechnology company harnessing biologically relevant protein states and physical artificial intelligence to create oral drugs for immune and inflammatory diseases | Funding round Verified against 2 sources | $25M | 2026-11-10 | [ LEAD ] |
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series B Verified against 1 of 75 sources | $133M | 2026-11-05 | [ PART ] |
R1 Therapeutics A biopharmaceutical company focused on developing therapies for kidney disease | Series A Developing, 2 sources | $3M | 2026-09-30 | [ PART ] |
Link Cell Therapies An oncology cell therapy company utilizing its proprietary logic-gating technology to develop next-generation CAR-T therapeutics for solid tumors and hematologic malignancies | Series A Verified against 4 of 6 sources | $30M | 2026-09-28 | [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series D Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $66M | 2026-08-18 | [ PART ] |
Coultreon Biopharma Develop autoimmune disease treatments | Series A Verified against 1 of 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $125M | 2026-04-28 | [ PART ] |
Sidewinder Therapeutics Sidewinder Therapeutics specializes in developing bispecific antibody-drug conjugates aimed at treating difficult cancers for patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $137M | 2026-04-08 | [ PART ] |
Ambrosia Biosciences Small molecule-based therapies for obesity and metabolic disorders, aimed at healthcare providers and patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-03-31 | [ PART ] |
EpiBiologics They develop bispecific antibodies designed to selectively degrade disease-causing extracellular proteins. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $107M | 2026-01-08 | [ PART ] |
Link Cell Therapies An oncology cell therapy company utilizing its proprietary logic-gating technology to develop next-generation CAR-T therapeutics for solid tumors and hematologic malignancies | Series A Verified against 1 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2025-12-15 | [ PART ] |
PsiThera A biotechnology company harnessing biologically relevant protein states and physical artificial intelligence to create oral drugs for immune and inflammatory diseases | Series A Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $47.5M | 2025-12-10 | [ LEAD ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-02-12 | [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $155M | 2023-08-17 | [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $42M | 2021-01-07 | [ PART ] |